Blood transfusion practices in cancer surgery

Area of Science:

• Oncology
• Transfusion Medicine
• Immunology

Background:

• Cancer patients frequently receive blood products like red blood cells (RBCs), fresh-frozen plasma (FFP), and platelets during major surgeries.
• Common indications for transfusion include blood loss, hemodilution, and coagulopathies.
• Transfusion-related immune modulation (TRIM) is a known complication, potentially impacting immune surveillance.

Purpose of the Study:

• To investigate the association between blood product administration and cancer recurrence and survival.
• To explore the potential mechanisms by which blood transfusions might influence tumor growth and metastasis.

Main Methods:

• Review of existing literature and meta-analyses examining blood transfusions in cancer surgery.
• Analysis of data linking blood product administration to patient outcomes such as recurrence-free survival and overall survival.

Main Results:

• Two meta-analyses indicate that blood product transfusion is linked to reduced recurrence-free and overall survival in colorectal cancer patients.
• Soluble factors in transfused blood products may directly promote tumor progression and spread.
• Decreased immune surveillance post-transfusion has been associated with cancer recurrence.

Conclusions:

• Blood product transfusion may negatively impact survival outcomes in cancer patients undergoing surgery.
• Further studies are essential to validate these findings in various cancer types and patient cohorts.
• Understanding the complex interactions between transfusion medicine and cancer biology is crucial for optimizing patient care.